A Mab A Case Study In Bioprocess Development Jun 2026

After capture, the eluate undergoes , typically using a low pH hold, which destroys enveloped viruses. Finally, two polishing chromatography steps are performed—anion exchange (AEX) and cation exchange (CEX)—to remove residual HCPs, DNA, and aggregated forms of the mAb. The entire chromatography process is itself optimized through the application of Analytical Quality by Design (AQbD) . For example, when a previous Protein-A HPLC method for titer quantitation proved unreliable, retrospective application of AQbD principles identified a bias from standard vial materials. By re-optimizing the method, the team reduced development timelines for new products by 50% and gained more accurate titer data.

The study emphasizes optimizing the inoculum expansion and bioreactor stages to enhance productivity while maintaining quality. This includes exploring critical process parameters (CPPs) that directly affect cell growth and antibody glycosylation.

During the bioprocess development of A Mab, several challenges were encountered, including:

A comparison of challenges for mAbs.

The purification process was scaled up from a 10 mL to a 100 L scale, demonstrating excellent scalability.

The success of "A Mab" was not in any single step, but in the systematic, risk-based integration of upstream and downstream unit operations — a blueprint for modern bioprocess development.

A-Mab: A Case Study in Bioprocess Development Published in 2009 by a collaboration of major biopharmaceutical companies, it provides a comprehensive framework for navigating product characterization, upstream cell cultivation, downstream purification, and risk-based regulatory filings. Rather than treating biological manufacturing as a rigid protocol, the A-Mab model illustrates how advanced process knowledge allows manufacturers to establish flexible operating bounds called a design space. 1. Foundations of the A-Mab Framework A Mab A Case Study In Bioprocess Development

At 10,000L scale, producing 100 kg/year of A Mab cost:

A two-stage depth filtration system was selected. The primary coarse filter captured whole cells and large fragments, while the secondary fine filter trapped sub-micron colloidal particles and nucleic acids.

The study employs tools like Failure Mode and Effects Analysis (FMEA) to assess how process parameters impact CQAs. After capture, the eluate undergoes , typically using

A tangential flow filtration (TFF) system with a 30 kDa regenerated cellulose membrane concentrated the mAb to its final target formulation of 100 mg/mL. It simultaneously exchanged the buffer into a histidine-sucrose formulation stabilizing the drug substance for long-term storage. 4. Analytical Characterization and Quality Control

"A-Mab: A Case Study in Bioprocess Development" is a 2009 document from the CMC Biotech Working Group illustrating the application of Quality by Design (QbD) principles to monoclonal antibody manufacturing. The 278-page study details the development, design space, and control strategies for a hypothetical product. Download the complete case study from International Society for Pharmaceutical Engineering (ISPE) A–Mab: A Case Study in Bioprocess Development - ISPE